CERE Investors Have Opportunity to Lead Cerevel Therapeutics Holdings, Inc. Securities Fraud Lawsuit

Published: Saturday, May 10, 2025 at 4:06 pm

Cerevel Therapeutics Investors Urged to Join Securities Fraud Lawsuit: Deadline Approaching

**NEW YORK, May 10, 2025** – Investors who purchased or held shares of Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) between October 11, 2023, and August 1, 2024, may be eligible to participate in a securities fraud class action lawsuit. The Rosen Law Firm, a prominent investor rights law firm, is spearheading the action, alleging that Cerevel and its controlling shareholders, Bain Capital and Pfizer, made false and misleading statements during a secondary stock offering and in a proxy statement.

The lawsuit centers around a secondary stock offering orchestrated by Bain Capital and Pfizer on October 16, 2023. The complaint alleges that this offering allowed Bain Capital to increase its stake in Cerevel at a discounted price, just before AbbVie Inc. announced its acquisition of Cerevel at a significantly higher price per share. This acquisition, announced just 51 days after the offering, resulted in a substantial windfall for Bain Capital, according to the lawsuit. Investors who purchased shares during the specified period, held shares as of the January 8, 2024 record date and were entitled to vote on the merger of Cerevel and AbbVie Inc., or sold shares contemporaneously with Bain Capital's purchase on or about October 16, 2023, may have suffered damages.

The deadline to apply to be the lead plaintiff in this case is **June 3, 2025**. Investors who wish to join the class action should visit the Rosen Law Firm's website or contact them directly. The firm emphasizes its experience and track record in securities litigation, highlighting its past successes in recovering significant funds for investors. The firm notes that investors may be entitled to compensation without paying any out-of-pocket fees through a contingency fee arrangement.

BNN's Perspective: While these types of lawsuits can be complex, it's crucial for investors to understand their rights and potential recourse when they believe they've been misled. The allegations, if proven true, raise serious questions about corporate transparency and fairness. Investors should carefully consider their options and consult with qualified legal counsel to determine the best course of action.

Keywords: Cerevel Therapeutics, CERE, securities fraud, class action lawsuit, Rosen Law Firm, Bain Capital, Pfizer, AbbVie, stock offering, investor rights, lead plaintiff, June 3 2025 deadline, NASDAQ, stock market, investor compensation, legal action, financial news, shareholder lawsuit, misleading statements, secondary stock offering

Full Coverage